Free tool
FAERS Monitor: Vitrakvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211710 or its brand name (Vitrakvi, Larotrectinib Sulfate). Reports on generic versions are filed under their own applications.
Reports
896
Serious
668
75% of reports
Hospitalization
173
Death reported
163
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness62
- fatigue62
- drug ineffective61
- death52
- neuropathy peripheral45
- pain44
- disease progression38
- nausea38
- off label use38
- myalgia27
- vomiting27
- diarrhoea23
- malignant neoplasm progression23
- anaemia21
- headache21
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 97 |
| 2020 | 138 |
| 2021 | 147 |
| 2022 | 137 |
| 2023 | 138 |
| 2024 | 93 |
| 2025 | 100 |
| 2026 | 46 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,263 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuropathy peripheralSignal | 45 | 11.1 | 8.4 | 406 |
| disease progressionSignal | 38 | 7.5 | 5.5 | 210 |
| malignant neoplasm progressionSignal | 23 | 5.3 | 3.5 | 76 |
| myalgiaSignal | 27 | 3.7 | 2.6 | 52 |
| dizzinessSignal | 62 | 2.9 | 2.3 | 78 |
| anaemiaSignal | 21 | 2.6 | 1.7 | 19 |
| fatigue | 62 | 1.9 | 1.5 | 25 |
| pain | 44 | 1.7 | 1.3 | 12 |
| death | 52 | 1.4 | 1.1 | 6 |
| vomiting | 27 | 1.3 | 0.9 | 2 |
| nausea | 38 | 1.1 | 0.8 | 0 |
| drug ineffective | 61 | 1.1 | 0.9 | 0 |
| off label use | 38 | 1.0 | 0.7 | 0 |
| diarrhoea | 23 | 0.8 | 0.6 | 1 |
| headache | 21 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.